DE05011213T1 - Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin - Google Patents

Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin Download PDF

Info

Publication number
DE05011213T1
DE05011213T1 DE05011213T DE05011213T DE05011213T1 DE 05011213 T1 DE05011213 T1 DE 05011213T1 DE 05011213 T DE05011213 T DE 05011213T DE 05011213 T DE05011213 T DE 05011213T DE 05011213 T1 DE05011213 T1 DE 05011213T1
Authority
DE
Germany
Prior art keywords
dosing interval
beginning
buprenorphine
hours
release rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE05011213T
Other languages
English (en)
Inventor
F. Robert Greenwich REDER
D. Paul Wilton GOLDENHEIM
F. Robert Weston KAIKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26715643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE05011213(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE05011213T1 publication Critical patent/DE05011213T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)

Abstract

Verwendung einer Polymermatrixschicht, umfassend Buprenorphin oder ein pharmazeutisch akzeptables Salz davon, und eine Stützschicht, die aus einem pharmazeutisch akzeptablen Material gefertigt ist, und welche für Buprenorphin undurchlässig ist, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, welches für die Behandlung von Schmerzen in einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringen des transdermalen Abgabesystems auf die Haut eines Patienten eine Freisetzungsrate an Buprenorphin über ungefähr ein 72 Stunden Dosierintervall bereitstellt, so dass eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml erreicht wird und die transdermale Abgabeeinheit, wenn sie auf der Haut des Patienten für ein zusätzliches 24 Stunden Intervall beibehalten wird, Plasmakonzentrationen an Buprenorphin in den Patienten oberhalb der minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames Schmerzmanagement erfahren.

Claims (8)

  1. Verwendung einer Polymermatrixschicht, umfassend Buprenorphin oder ein pharmazeutisch akzeptables Salz davon, und eine Stützschicht, die aus einem pharmazeutisch akzeptablen Material gefertigt ist, und welche für Buprenorphin undurchlässig ist, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, welches für die Behandlung von Schmerzen in einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringen des transdermalen Abgabesystems auf die Haut eines Patienten eine Freisetzungsrate an Buprenorphin über ungefähr ein 72 Stunden Dosierintervall bereitstellt, so dass eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml erreicht wird und die transdermale Abgabeeinheit, wenn sie auf der Haut des Patienten für ein zusätzliches 24 Stunden Intervall beibehalten wird, Plasmakonzentrationen an Buprenorphin in den Patienten oberhalb der minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames Schmerzmanagement erfahren.
  2. Verwendung eines transdermalen Abgabesystems für Buprenorphin, das vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls eine mittlere Freisetzungsrate von 3 μg/Std. bis 86 μg/Std. an Buprenorphin bereitstellt und, basierend auf einem transdermalen Abgabesystem mit 10 mg Buprenorphin, von 72 Stunden nach dem Beginn des Dosierintervalls bis mindestens 96 Stunden nach dem Beginn des Dosierintervalls eine mittlere Freisetzungsrate von 0,3 μg/Std. bis 9 μg/Std. bereitstellt, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, das für die Behandlung von Schmerzen bei einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringung des transdermalen Abgabesystems auf die Haut eines Patienten über ein 72 Stunden Dosierintervall eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml bereitstellt, und, wenn es für ein zusätzliches 24 Stundenintervall auf der Haut des Patienten beibehalten wird, Plasmakonzentrationen an Buprenorphin oberhalb den minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames ein Schmerzmanagement erfahren.
  3. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 3 μg/Std. bis 5 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 0,3 μg/Std. bis 0,6 μg/Std. von 72 Stunden nach Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  4. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 6 μg/Std. bis 11 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 0,7 μg/Std. bis 1 μg/Std. bis 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  5. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 13 μg/Std. bis 21 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 1 μg/Std. bis 2 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  6. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 26 μg/Std. bis 43 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 3 μg/Std. bis 4 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  7. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 39 μg/Std. bis 64 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 4 μg/Std. bis 7 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
  8. Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 51 μg/Std. bis 86 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 5 μg/Std. bis 9 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
DE05011213T 1997-02-24 1998-02-24 Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin Pending DE05011213T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3891997P 1997-02-24 1997-02-24
US38919P 1997-02-24
US939068 1997-09-29
US08/939,068 US5968547A (en) 1997-02-24 1997-09-29 Method of providing sustained analgesia with buprenorphine

Publications (1)

Publication Number Publication Date
DE05011213T1 true DE05011213T1 (de) 2007-09-06

Family

ID=26715643

Family Applications (2)

Application Number Title Priority Date Filing Date
DE05011213T Pending DE05011213T1 (de) 1997-02-24 1998-02-24 Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
DE69835584T Expired - Lifetime DE69835584T2 (de) 1997-02-24 1998-02-24 Verzögerte analgesie erreicht mit transdermaler verabreichung von buprenorphin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69835584T Expired - Lifetime DE69835584T2 (de) 1997-02-24 1998-02-24 Verzögerte analgesie erreicht mit transdermaler verabreichung von buprenorphin

Country Status (22)

Country Link
US (15) US5968547A (de)
EP (9) EP2305192A1 (de)
JP (1) JP2000511936A (de)
KR (1) KR100703101B1 (de)
CN (2) CN1827107B (de)
AT (3) ATE336212T1 (de)
AU (2) AU2004218685B2 (de)
BR (1) BR9815439A (de)
CA (1) CA2276170C (de)
CZ (2) CZ299414B6 (de)
DE (2) DE05011213T1 (de)
DK (4) DK1731152T3 (de)
ES (4) ES2380023T3 (de)
HK (3) HK1096847A1 (de)
HU (3) HU230374B1 (de)
IL (4) IL131561A0 (de)
NO (11) NO322515B1 (de)
NZ (1) NZ337386A (de)
PL (1) PL196086B1 (de)
PT (4) PT964677E (de)
SI (3) SI1570823T1 (de)
WO (1) WO1998036728A2 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
WO1999032119A1 (en) 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
CA2400578C (en) * 2000-02-08 2007-01-02 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1280485A4 (de) * 2000-02-29 2006-11-29 Zars Inc Verbessertes transdermales medizinpflaster
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
AU2001262683A1 (en) * 2000-06-02 2001-12-17 Teijin Limited Buprenorphine-containing patch
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
WO2002034206A2 (en) * 2000-10-23 2002-05-02 Euro-Celtique, S.A. Felodipine transdermal device and methods
DE60141596D1 (de) 2000-10-23 2010-04-29 Euro Celtique Sa Transdermales system zur verabreichung von loratadin und dessen verwendung
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
WO2002083135A2 (en) * 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
DK1368023T3 (da) * 2001-02-16 2006-02-13 Gruenenthal Chemie Anvendelse af buprenoprphin til behandling af urininkontinens
KR20030088445A (ko) * 2001-03-02 2003-11-19 유로-셀티큐 에스.에이. Ｎ-부-3-테닐 노르부프레노르핀 및 사용방법
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
DE60230632D1 (de) 2001-07-18 2009-02-12 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JPWO2003014247A1 (ja) * 2001-08-10 2005-01-13 有限会社コスメディ 皮膚用粘着剤及びそれを用いた皮膚用テープ又はシート
EP1455784A1 (de) * 2001-12-17 2004-09-15 Aryx Therapeutics Schmerzmittelabgabesystem und verfahren zur verwendung desselbigen
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
JP2005528359A (ja) * 2002-03-20 2005-09-22 ユーロ−セルティーク エス．エイ． うつ病の治療のためのブプレノルフィンの投与方法
EP2243471A1 (de) 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix für die modifizierte Freigabe von aktiven Substanzen
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
KR101407131B1 (ko) 2002-06-10 2014-06-19 유로-셀티크 소시에떼 아노뉨 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
PT1526848E (pt) * 2002-08-09 2007-08-08 Gruenenthal Gmbh Antagonistas dos receptores de opióides em sistemas transdérmicos contendo buprenorfina
JP4642467B2 (ja) * 2002-08-20 2011-03-02 ユーロ−セルティーク エス．エイ． 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
EP1545468A4 (de) * 2002-09-20 2007-06-20 Alpharma Inc Opioid-formulierungen mit verz gerter freisetzung und anwendungsverfahren
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US7084150B2 (en) * 2002-10-25 2006-08-01 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
EP1913938A1 (de) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermales Dosierungsschema für Buprenorphin zur Schmerzstillung
DK1572167T3 (da) * 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8778382B2 (en) 2003-04-30 2014-07-15 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
KR20090031961A (ko) * 2003-07-25 2009-03-30 유로-셀티큐 에스.에이. 수술후 통증의 수술전 치료
ES2295929T3 (es) 2003-07-25 2008-04-16 Euro-Celtique S.A. Tratamiento de suspension de la dependencia.
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
DE602005013490D1 (de) 2004-02-23 2009-05-07 Euro Celtique Sa Missbrauchsichere transdermale abgabevorrichtung für opioide, enthaltend opioidantagonist in form von mikrokügelchen
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1743638A1 (de) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Formulierungen von substituierten Pyrazolinderivaten
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
CA2935569A1 (en) * 2006-04-13 2007-10-25 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
CN101677963B (zh) 2006-06-19 2012-05-30 奥尔制药公司 药物组合物
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US20110008431A1 (en) * 2007-04-02 2011-01-13 Toyo Boseki Kabushiki Kaisha Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
DK2182902T3 (en) * 2007-08-07 2015-04-13 Acelrx Pharmaceuticals Inc Compositions comprising sufentanil and triazolam for procedure sedation and analgesia using oral transmucosal dosage forms
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
ES2663777T3 (es) * 2008-06-23 2018-04-17 Biodelivery Sciences International, Inc. Dispositivos de administración mucosa multidireccionales y métodos de uso
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
DK2405915T3 (en) 2009-03-10 2019-02-11 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110037455A1 (en) * 2009-08-17 2011-02-17 Oren Navot System for measuring electrical power
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
PT2611445T (pt) * 2010-09-03 2018-10-24 Zoetis Belgium S A Composições de buprenorfina de dose elevada e utilização como analgésico
EP2606895A4 (de) * 2010-10-12 2014-04-02 Univ Wuhan Pflaster zur transdermalen absorption eines antivirus-wirkstoffs und verfahren zu seiner herstellung
DK2640389T3 (en) * 2010-11-17 2015-03-09 Hexal Ag Transdermal therapeutic system comprising buprenorphine
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
EP2758134B1 (de) * 2011-09-19 2019-05-29 Carmel - Haifa University Economic Corporation Ltd. Buprenorphin zur behandlung von akuter suizidalität
SG11201403162XA (en) * 2011-12-12 2014-10-30 Lohmann Therapie Syst Lts Transdermal delivery system comprising buprenorphine
CN104125828A (zh) * 2011-12-21 2014-10-29 拜欧帝力威瑞科学有限公司 用于慢性疼痛缓解的跨粘膜药物传递装置
US20130211351A1 (en) * 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2882870C (en) * 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014105480A1 (en) * 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
CN105377245B (zh) 2013-06-04 2018-07-17 Lts勒曼治疗系统股份公司 透皮递送系统
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
MY187877A (en) 2014-12-23 2021-10-26 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
NZ735736A (en) 2015-03-10 2019-02-22 Rhodes Tech Acetate salt of buprenorphine and methods for preparing buprenorphine
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3092757A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine
EP4238669A1 (de) 2022-03-02 2023-09-06 Recutech S.r.o. Verfahren zur herstellung einer wärme-feuchtigkeitsaustauschplatte eines enthalpie-luft-zu-luft-austauschers, wärme-feuchtigkeitsaustauschplatte und eines enthalpietauscher

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4058599A (en) 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4119713A (en) 1977-02-09 1978-10-10 Sam Carosio Analgesic and anti-inflammatory composition
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
DE3330750A1 (de) * 1983-08-26 1985-03-14 Chemische Werke Hüls AG, 4370 Marl Verfahren zur erzeugung von acetylen und synthese- oder reduktionsgas aus kohle in einem lichtbogenprozess
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4636539A (en) 1984-01-30 1987-01-13 Loctite (Ireland) Limited Instant adhesive composition utilizing calixarene accelerators
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
DE3546830C2 (de) 1984-07-23 1995-07-20 Alza Corp Transdermales Abgabesystem zur Verabreichung von Fentanyl
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4834978A (en) 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
US5171576A (en) 1987-03-09 1992-12-15 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3812481A1 (de) * 1987-08-26 1989-03-09 Bayer Ag Wasserhaertende polymerzubereitung
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
US5336210A (en) * 1989-02-28 1994-08-09 Teijin Limited Plaster agent
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
DE3939376C1 (de) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (de) * 1989-12-12 1991-06-19 Warner-Lambert Company Transdermales Abgabesystem zur Behandlung der Kokain- und Heroinsucht
JP2849937B2 (ja) * 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
KR950005865B1 (ko) * 1990-04-23 1995-06-02 데이진 가부시끼가이샤 첩부제
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
US5688547A (en) 1990-08-03 1997-11-18 American Cyanamid Company Meal replacement composition and method of weight control
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CN1036343C (zh) 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法
PL166095B1 (pl) 1991-04-03 1995-03-31 Warszawskie Zaklady Farma Sposób wytwarzania N-cyklopropylometylo-7a -[(S)-1-hydroksy-1,2,2-trimetylopropylo] endo-etano-6,7,8,14-tetrahydronororipaviny
HUT69390A (en) 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5272149A (en) 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
MX9302812A (es) 1992-05-13 1993-11-01 Alza Corp Administracion transdermica de oxibutinina.
JPH08501529A (ja) 1992-06-11 1996-02-20 セラテック・インコーポレイテッド 皮膚透過薬剤投与緩和のグリセリン使用
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4237453C1 (de) 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
JP3489831B2 (ja) 1993-04-20 2004-01-26 ヘクサル・アクチエンゲゼルシャフト 活性成分パッチ
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
ATE149349T1 (de) 1993-06-25 1997-03-15 Alza Corp Einarbeitung eines poly-n-vinylamids in ein transdermales system
AU7566994A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
WO1995019991A1 (en) 1994-01-20 1995-07-27 Akzo Nobel N.V. New composition of glycoprotein isoforms having follicle stimulating activity
JPH07206710A (ja) * 1994-01-21 1995-08-08 Nitto Denko Corp 経皮投薬用テープ製剤
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5468457A (en) 1994-12-22 1995-11-21 Osram Sylvania Inc. Method of making tungsten-copper composite oxides
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
AU6657396A (en) 1995-07-28 1997-02-26 Novartis Ag Transdermal system
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
FR2739731B1 (fr) 1995-10-09 1998-01-02 Axon Cable Sa Procede de raccordement de micro-cables coaxiaux aux pistes d'un circuit imprime
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US5792740A (en) 1996-03-08 1998-08-11 Firmenich Sa Fragrant macrocyclic lactones
PT889723E (pt) 1996-03-25 2002-11-29 Lohmann Therapie Syst Lts Sistema terapeutico transdermico com pequena espressura da zona de aplicacao e elevada flexibilidade assim como processo de producao
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
EP0821957A3 (de) 1996-08-01 1998-04-22 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
AT405158B (de) * 1996-12-04 1999-06-25 Steyr Daimler Puch Ag Verfahren zur selbsttätigen steuerung der sperrkupplungen eines allradgetriebenen fahrzeuges und fahrzeug mit knicklenkung und sperrbaren differentialen
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
CA2280033A1 (en) 1997-02-07 1998-08-13 Susan Rako Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU7273898A (en) 1997-04-30 1998-11-24 Human Pheromone Sciences, Inc. Method of fixing fragrances in fragrance composition and other compositions
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5900420A (en) 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
UA53774C2 (uk) 1997-12-22 2003-02-17 Еро-Селтік, С.А. Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди
AU2981099A (en) 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP1064035B1 (de) 1998-03-23 2003-11-26 ELAN CORPORATION, Plc Vorrichtung zur arzneimittelverarbreichung
EP1079813B1 (de) 1998-04-29 2005-02-09 Virotex Corporation Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
DE19840758A1 (de) 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit
KR100383252B1 (ko) 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
IT1305303B1 (it) 1999-03-10 2001-05-04 Farmigea Spa Uso dell'olio essenziale di niaouli come promotore per la permeazionetransdermica.
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6554851B1 (en) 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ATE460939T1 (de) 2000-08-30 2010-04-15 Unimed Pharmaceuticals Llc Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
KR20030088445A (ko) 2001-03-02 2003-11-19 유로-셀티큐 에스.에이. Ｎ-부-3-테닐 노르부프레노르핀 및 사용방법
DE60236496D1 (de) 2001-03-23 2010-07-08 Einstein Coll Med Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
PT2113315E (pt) 2001-04-23 2014-08-25 Euro Celtique Sa Sistema de eliminação para uma forma de dosagem transdérmica
DE60230138D1 (de) 2001-05-01 2009-01-15 Euro Celtique Sa Vor missbrauch geschützte opioid-haltige transdermale systeme
JP4302991B2 (ja) 2001-05-22 2009-07-29 ユーロ−セルティーク エス．エイ． 経皮性剤形を分配する容器及び装置
CN1539028A (zh) 2001-06-04 2004-10-20 ���ڵٿ����޹�˾ 形成图案的方法
AU2002355266A1 (en) 2001-07-23 2003-02-17 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
AU2002348135A1 (en) 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
JP2005528359A (ja) 2002-03-20 2005-09-22 ユーロ−セルティーク エス．エイ． うつ病の治療のためのブプレノルフィンの投与方法
ATE382050T1 (de) 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
ES2295929T3 (es) * 2003-07-25 2008-04-16 Euro-Celtique S.A. Tratamiento de suspension de la dependencia.
KR20090031961A (ko) 2003-07-25 2009-03-30 유로-셀티큐 에스.에이. 수술후 통증의 수술전 치료
AU2004266731A1 (en) 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-HT agonists across the oral mucosa and methods of use thereof
AU2006242246A1 (en) 2005-05-03 2006-11-09 Innozen, Inc. Edible film for transmucosal delivery of nutritional supplements
AU2006326377B2 (en) 2005-12-13 2010-10-07 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
EP2452683A3 (de) 2006-06-26 2012-08-22 Amgen Inc. Verfahren zur Behandlung von Atherosklerose
KR101230804B1 (ko) 2006-07-21 2013-02-08 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
HUE038022T4 (hu) 2006-10-02 2023-02-28 Spepharm Ag Nem mukoadhezív filmdózisformák
CA2665387A1 (en) 2006-10-03 2008-04-10 University Of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
WO2008115811A2 (en) 2007-03-16 2008-09-25 Endo Pharmaceuticals, Inc. Transdermal delivery form disposal systems and methods
ES2663777T3 (es) 2008-06-23 2018-04-17 Biodelivery Sciences International, Inc. Dispositivos de administración mucosa multidireccionales y métodos de uso
DK2640389T3 (en) 2010-11-17 2015-03-09 Hexal Ag Transdermal therapeutic system comprising buprenorphine

Also Published As

Publication number Publication date
AU2004218685A1 (en) 2004-11-04
AU6184198A (en) 1998-09-09
NO329838B1 (no) 2011-01-10
BR9815439A (pt) 2001-10-16
USRE41571E1 (en) 2010-08-24
DK2305194T3 (da) 2012-08-13
EP0964677A1 (de) 1999-12-22
NO2017011I1 (no) 2017-04-04
NO20151450A1 (no) 1999-10-22
US9642850B2 (en) 2017-05-09
EP2305194B1 (de) 2012-05-09
CA2276170A1 (en) 1998-08-27
NO333139B1 (no) 2013-03-11
NO20131533L (no) 1999-10-22
ATE336212T1 (de) 2006-09-15
NO20120563L (no) 1999-10-22
US5968547A (en) 1999-10-19
CN1252705A (zh) 2000-05-10
CN1827107A (zh) 2006-09-06
US6231886B1 (en) 2001-05-15
KR20000075648A (ko) 2000-12-26
NO20101190L (no) 1999-10-22
AU2008261134A1 (en) 2009-01-15
AU2925402A (en) 2002-05-16
HUP1200599A2 (en) 2000-12-28
SI0964677T1 (sl) 2006-12-31
PL196086B1 (pl) 2007-12-31
CA2276170C (en) 2007-12-04
PT964677E (pt) 2006-12-29
NZ337386A (en) 2001-06-29
EP2305192A1 (de) 2011-04-06
EP1731152A2 (de) 2006-12-13
HUP0002342A3 (en) 2001-04-28
PT1731152E (pt) 2013-07-31
US20010002259A1 (en) 2001-05-31
CZ2015477A3 (cs) 2015-10-21
IL131561A (en) 2010-05-31
US20060216340A1 (en) 2006-09-28
EP1731152B1 (de) 2013-05-01
NO2016013I1 (no) 2016-07-18
SI1570823T1 (sl) 2012-03-30
PT2305194E (pt) 2012-08-14
NO994087L (no) 1999-10-22
WO1998036728A3 (en) 1998-12-10
AU2004218685B2 (en) 2009-01-22
HU230374B1 (hu) 2016-03-29
US20110288112A1 (en) 2011-11-24
NO334290B1 (no) 2014-01-27
USRE41408E1 (en) 2010-06-29
NO340067B1 (no) 2017-03-06
AU774779B2 (en) 2004-07-08
KR100703101B1 (ko) 2007-04-06
EP1731152A3 (de) 2007-11-14
ES2271988T3 (es) 2007-04-16
US20030091631A1 (en) 2003-05-15
US20160220559A1 (en) 2016-08-04
DK1570823T3 (da) 2012-02-20
HK1103621A1 (en) 2007-12-28
NO20111441L (no) 1999-10-22
DK0964677T3 (da) 2006-12-11
US20030198675A1 (en) 2003-10-23
NO20064395L (no) 1999-10-22
CZ299414B6 (cs) 2008-07-16
HU230608B1 (hu) 2017-03-28
HUP1500370D0 (hu) 2000-12-28
PT1570823E (pt) 2012-03-02
EP0964677A4 (de) 2002-12-18
NO994087D0 (no) 1999-08-24
ATE556682T1 (de) 2012-05-15
CN1827107B (zh) 2010-05-26
DE69835584D1 (de) 2006-09-28
CZ300999A3 (cs) 2000-03-15
AU2008261134B2 (en) 2012-08-02
US6344212B2 (en) 2002-02-05
EP2305193A1 (de) 2011-04-06
NO322515B1 (no) 2006-10-16
IL207067A (en) 2011-12-29
US20170056393A1 (en) 2017-03-02
DK1731152T3 (da) 2013-07-22
ES2423925T3 (es) 2013-09-25
EP2301493A1 (de) 2011-03-30
AU743071B2 (en) 2002-01-17
EP2305191A1 (de) 2011-04-06
IL201437A (en) 2010-12-30
JP2000511936A (ja) 2000-09-12
EP1570823A2 (de) 2005-09-07
US20150157625A1 (en) 2015-06-11
NO332248B1 (no) 2012-08-06
ES2380023T3 (es) 2012-05-07
EP1570823B1 (de) 2011-12-28
NO20130298L (no) 1999-10-22
NO329734B1 (no) 2010-12-13
US20130197020A1 (en) 2013-08-01
ATE538765T1 (de) 2012-01-15
US20140073663A1 (en) 2014-03-13
EP2301494A1 (de) 2011-03-30
EP2305194A1 (de) 2011-04-06
NO337094B1 (no) 2016-01-18
WO1998036728A2 (en) 1998-08-27
HK1096847A1 (en) 2007-06-15
PL335306A1 (en) 2000-04-10
EP1570823A3 (de) 2006-01-18
NO20074292L (no) 1999-10-22
NO333374B1 (no) 2013-05-13
SI2305194T1 (sl) 2012-10-30
HUP0002342A2 (hu) 2000-12-28
ES2387752T3 (es) 2012-10-01
IL131561A0 (en) 2001-01-28
USRE41489E1 (en) 2010-08-10
DE69835584T2 (de) 2007-08-16
HK1153377A1 (en) 2012-03-30
EP0964677B1 (de) 2006-08-16

Similar Documents

Publication Publication Date Title
DE05011213T1 (de) Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
DE60100595T2 (de) Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson
DE60100994T2 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
CA2528160A1 (en) Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
WO2008061625A2 (de) Transdermales therapeutisches system zur verabreichung des wirkstoffs buprenorphin
CA2314326A1 (en) Transdermal therapeutic device and method with capsaicin and capsaicin analogs
WO1998008546A3 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
DD296844A5 (de) Verfahren zur herstellung eines pflasters als transdermales therapeutisches system zur verabreichung von wirkstoffen an die haut mit einer abgestuften wirkstoffabgabe sowie verwendung
WO2001013902A2 (de) Wirkstoffkombination enthaltend clonidin und pramipexol
Caraceni et al. Study of the excitability cycle of the blink reflex in Huntington’s chorea
DE19654468C1 (de) Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung
EP1978995A1 (de) Verfahren zur behandlung und/oder prophylaxe von multipler sklerose, sowie verwendung von erythropoietin zur herstellung eines arzneimittels zur intermittierenden behandlung und/oder intermittierenden prophylaxe von multipler sklerose
DE19746191C2 (de) Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
DE2006696A1 (de) Pflaster oder Haftverband
DE19850517B4 (de) Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
Vazquez et al. The effects of sensory stimulation on REM sleep duration
WO2006030030A2 (de) System zur sequentiellen, transdermalen verabreichung von systemisch wirksamen substanzen
Maier Calcitonin
DE60024408T2 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE10293600B4 (de) Rezeptoradaptierter Nikotinentzug durch anticholinerge und noradrenerge Blockade
DE10133576A1 (de) Verwendung von physiologisch aktiven Oligopeptiden zur Stabilisierung des Immunsystems
DE2057174A1 (de) Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum
Rezaković et al. Acute and chronic efficacy of 10 mg of nitroglycerin patch in stable angina pectoris
DE4218292C1 (de) Verwendung eines Arzneimittels mit einem Gehalt an Mestanolon und/oder 4-Chlor-1-dehydromethyltestosteron
DE4303530C2 (de) Pharmazeutische Verwendung eines Enkephalins